(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed in a second late-stage study, sending shares of the company down ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related epilepsy.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava Sciences, Inc.’s SAVA share price has dipped by 20.00%, which has investors questioning if this is right time to buy.

Cassava said that it will discontinue all efforts to develop simufilam and expects to phase out the program by the end of the second quarter. Still, the biotechnology company said it has begun ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

Simufilam continued to demonstrate an overall favorable safety profile. About REFOCUS-ALZ Cassava Sciences NewsMORE Related Stocks ...

In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs ...